Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 5

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 5
---
 are referred to without the ® and ™ symbols, but such references should not be construed as any indicator
that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the
use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us
by, any other companies.

As of November 1, 2022,
our reporting currency and functional currency is the United States Dollar. Prior to that, our reporting currency and functional currency
was the Canadian Dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus to “CAD$”
are to Canadian Dollars. Amounts denominated in United States Dollars are states as “$” “dollars” or “USD”.
Where previously disclosed financial information was in Canadian Dollars, we have included a convenience translation.

This prospectus includes
statistical, market and industry data and forecasts which we obtained from publicly available information and independent industry publications
and reports that we believe to be reliable sources. These publicly available industry publications and reports generally state that they
obtain their information from sources that they believe to be reliable, but they do not guarantee the accuracy or completeness of the
information.

We report under International
Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB. None of the financial
statements were prepared in accordance with generally accepted accounting principles in the United States.

On September 30, 2022, we effected a one-for-30
consolidation of our issued and outstanding common shares. In addition, on November 28, 2023, we effected a one-for-30 consolidation
of our issued and outstanding common shares. Except where otherwise indicated, all share and per share data in this prospectus supplement
have been retroactively restated to reflect the aforementioned consolidations.

<div align='center'>ii

PROSPECTUS SUMMARY</div>

This summary highlights information contained elsewhere in or incorporated by reference into this prospectus that we consider important. This summary does not contain all of the information you should consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk Factors” section and the financial statements and related notes incorporated by reference into this prospectus and the other documents incorporated by reference into this prospectus, which are described under “Incorporation by Reference” before making an